O	0	8	Clinical	Clinical	JJ	B-NP
O	9	20	implication	implication	NN	I-NP
O	21	23	of	of	IN	B-PP
O	24	34	expression	expression	NN	B-NP
O	35	37	of	of	IN	B-PP
O	38	52	cyclooxygenase	cyclooxygenase	NN	B-NP
O	52	53	-	-	HYPH	B-NP
O	53	54	2	2	CD	I-NP
O	55	58	and	and	CC	O
O	59	69	peroxisome	peroxisome	NN	B-NP
O	70	82	proliferator	proliferator	NN	I-NP
O	83	92	activated	activate	VBN	B-VP
O	92	93	-	-	HYPH	B-NP
O	93	101	receptor	receptor	NN	I-NP
O	102	107	gamma	gamma	NN	I-NP
O	108	110	in	in	IN	B-PP
B-Cancer	111	121	epithelial	epithelial	JJ	B-NP
I-Cancer	122	129	ovarian	ovarian	JJ	I-NP
I-Cancer	130	137	tumours	tumour	NNS	I-NP
O	137	138	.	.	.	O

O	140	150	Expression	Expression	NN	B-NP
O	151	153	of	of	IN	B-PP
O	154	168	cyclooxygenase	cyclooxygenase	NN	B-NP
O	169	170	(	(	(	O
O	170	173	COX	COX	NN	B-NP
O	173	174	)	)	)	O
O	174	175	-	-	HYPH	B-NP
O	175	176	2	2	CD	I-NP
O	177	182	plays	play	VBZ	B-VP
O	183	184	a	a	DT	B-NP
O	185	188	key	key	JJ	I-NP
O	189	193	role	role	NN	I-NP
O	194	196	in	in	IN	B-PP
O	197	210	tumorigenesis	tumorigenesis	NN	B-NP
O	211	214	and	and	CC	O
O	215	226	development	development	NN	B-NP
O	227	230	and	and	CC	O
O	231	241	peroxisome	peroxisome	NN	B-NP
O	242	254	proliferator	proliferator	NN	I-NP
O	254	255	-	-	HYPH	B-NP
O	255	264	activated	activate	VBN	I-NP
O	265	273	receptor	receptor	NN	I-NP
O	274	279	gamma	gamma	NN	I-NP
O	280	281	(	(	(	O
O	281	290	PPARgamma	PPARgamma	NN	B-NP
O	290	291	)	)	)	O
O	292	295	has	have	VBZ	B-VP
O	296	300	been	be	VBN	I-VP
O	301	311	implicated	implicate	VBN	I-VP
O	312	314	in	in	IN	B-PP
O	315	318	the	the	DT	B-NP
O	319	326	control	control	NN	I-NP
O	327	329	of	of	IN	B-PP
O	330	333	COX	COX	NN	B-NP
O	333	334	-	-	HYPH	O
O	334	335	2	2	CD	B-NP
O	336	346	expression	expression	NN	I-NP
O	347	349	in	in	IN	B-PP
O	350	354	some	some	DT	B-NP
B-Tissue	355	362	tissues	tissue	NNS	I-NP
O	362	363	.	.	.	O

O	364	367	The	The	DT	B-NP
O	368	371	aim	aim	NN	I-NP
O	372	374	of	of	IN	B-PP
O	375	379	this	this	DT	B-NP
O	380	385	study	study	NN	I-NP
O	386	388	is	be	VBZ	B-VP
O	389	391	to	to	TO	B-VP
O	392	403	investigate	investigate	VB	I-VP
O	404	405	(	(	(	B-LST
O	405	406	1	1	LS	I-LST
O	406	407	)	)	)	O
O	408	415	whether	whether	IN	B-SBAR
O	416	426	expression	expression	NN	B-NP
O	427	429	of	of	IN	B-PP
O	430	433	COX	COX	NN	B-NP
O	433	434	-	-	HYPH	B-NP
O	434	435	2	2	CD	I-NP
O	436	439	and	and	CC	O
O	440	449	PPARgamma	PPARgamma	NN	B-NP
O	450	452	is	be	VBZ	B-VP
O	453	463	associated	associate	VBN	I-VP
O	464	468	with	with	IN	B-PP
B-Organ	469	476	ovarian	ovarian	JJ	B-NP
O	477	491	carcinogenesis	carcinogenesis	NN	I-NP
O	492	495	and	and	CC	I-NP
O	496	507	progression	progression	NN	I-NP
O	508	510	of	of	IN	B-PP
B-Cancer	511	518	ovarian	ovarian	JJ	B-NP
I-Cancer	519	526	tumours	tumour	NNS	I-NP
O	527	530	and	and	CC	O
O	531	532	(	(	(	B-LST
O	532	533	2	2	LS	I-LST
O	533	534	)	)	)	O
O	535	542	whether	whether	IN	B-SBAR
O	543	546	COX	COX	NN	B-NP
O	546	547	-	-	HYPH	O
O	547	548	2	2	CD	B-NP
O	549	559	expression	expression	NN	I-NP
O	560	562	is	be	VBZ	B-VP
O	563	573	controlled	control	VBN	I-VP
O	574	581	through	through	IN	B-PP
O	582	588	ligand	ligand	NN	B-NP
O	588	589	-	-	HYPH	B-NP
O	589	597	mediated	mediate	VBN	I-NP
O	598	608	activation	activation	NN	I-NP
O	609	611	of	of	IN	B-PP
O	612	621	PPARgamma	PPARgamma	NN	B-NP
O	622	624	in	in	IN	B-PP
B-Cell	625	632	ovarian	ovarian	JJ	B-NP
I-Cell	633	642	carcinoma	carcinoma	NN	I-NP
I-Cell	643	648	cells	cell	NNS	I-NP
O	648	649	.	.	.	O

O	650	653	For	For	IN	B-PP
O	654	658	this	this	DT	B-NP
O	659	666	purpose	purpose	NN	I-NP
O	666	667	,	,	,	O
O	668	671	the	the	DT	B-NP
O	672	680	presence	presence	NN	I-NP
O	681	683	of	of	IN	B-PP
O	684	687	COX	COX	NN	B-NP
O	687	688	-	-	HYPH	B-NP
O	688	689	2	2	CD	I-NP
O	690	693	and	and	CC	O
O	694	703	PPARgamma	PPARgamma	NN	B-NP
O	704	707	was	be	VBD	B-VP
O	708	729	immunohistochemically	immunohistochemically	RB	I-VP
O	730	738	examined	examine	VBN	I-VP
O	739	741	in	in	IN	B-PP
O	742	744	71	71	CD	B-NP
B-Cancer	745	755	epithelial	epithelial	JJ	I-NP
I-Cancer	756	763	ovarian	ovarian	JJ	I-NP
I-Cancer	764	774	carcinomas	carcinoma	NNS	I-NP
O	774	775	,	,	,	O
O	776	778	18	18	CD	B-NP
B-Cancer	779	789	borderline	borderline	JJ	I-NP
I-Cancer	790	797	tumours	tumour	NNS	I-NP
O	798	801	and	and	CC	O
O	802	804	23	23	CD	B-NP
B-Pathological_formation	805	811	benign	benign	JJ	I-NP
I-Pathological_formation	812	819	tumours	tumour	NNS	I-NP
O	820	823	and	and	CC	O
O	824	827	the	the	DT	B-NP
O	828	834	levels	level	NNS	I-NP
O	835	837	of	of	IN	B-PP
O	838	841	COX	COX	NN	B-NP
O	841	842	-	-	HYPH	B-NP
O	842	843	2	2	CD	I-NP
O	844	847	and	and	CC	I-NP
O	848	857	PPARgamma	PPARgamma	NN	I-NP
O	858	866	proteins	protein	NNS	I-NP
O	867	871	were	be	VBD	B-VP
O	872	882	determined	determine	VBN	I-VP
O	883	885	by	by	IN	B-PP
O	886	892	enzyme	enzyme	NN	B-NP
O	893	904	immunoassay	immunoassay	NN	I-NP
O	905	907	in	in	IN	B-PP
O	908	912	four	four	CD	B-NP
B-Pathological_formation	913	919	benign	benign	JJ	I-NP
I-Pathological_formation	920	927	tumours	tumour	NNS	I-NP
O	927	928	,	,	,	O
O	929	934	three	three	CD	B-NP
B-Cancer	935	945	borderline	borderline	JJ	I-NP
I-Cancer	946	953	tumours	tumour	NNS	I-NP
O	954	957	and	and	CC	O
O	958	960	12	12	CD	B-NP
B-Cancer	961	971	carcinomas	carcinoma	NNS	I-NP
O	971	972	.	.	.	O

O	973	976	The	The	DT	B-NP
O	977	986	frequency	frequency	NN	I-NP
O	987	989	of	of	IN	B-PP
O	990	993	COX	COX	NN	B-NP
O	993	994	-	-	HYPH	B-NP
O	994	995	2	2	CD	I-NP
O	996	999	and	and	CC	O
O	1000	1009	PPARgamma	PPARgamma	NN	B-NP
O	1010	1019	detection	detection	NN	I-NP
O	1020	1023	was	be	VBD	B-VP
O	1024	1037	significantly	significantly	RB	I-VP
O	1038	1047	increased	increase	VBN	I-VP
O	1048	1051	and	and	CC	O
O	1052	1061	decreased	decrease	VBN	B-VP
O	1062	1064	as	as	IN	B-PP
B-Pathological_formation	1065	1072	lesions	lesion	NNS	B-NP
O	1073	1083	progressed	progress	VBN	B-VP
O	1084	1086	to	to	TO	B-PP
B-Cancer	1087	1096	carcinoma	carcinoma	NN	B-NP
O	1096	1097	,	,	,	O
O	1098	1110	respectively	respectively	RB	B-ADVP
O	1110	1111	.	.	.	O

O	1112	1115	The	The	DT	B-NP
O	1116	1119	COX	COX	NN	I-NP
O	1119	1120	-	-	HYPH	I-NP
O	1120	1121	2	2	CD	I-NP
O	1122	1129	protein	protein	NN	I-NP
O	1130	1133	was	be	VBD	B-VP
O	1134	1137	not	not	RB	I-VP
O	1138	1146	detected	detect	VBN	I-VP
O	1147	1149	in	in	IN	B-PP
O	1150	1153	the	the	DT	B-NP
O	1154	1159	three	three	CD	I-NP
B-Cancer	1160	1170	borderline	borderline	JJ	I-NP
I-Cancer	1171	1178	tumours	tumour	NNS	I-NP
O	1178	1179	,	,	,	O
O	1180	1187	whereas	whereas	IN	O
O	1188	1197	PPARgamma	PPARgamma	NN	B-NP
O	1198	1205	protein	protein	NN	I-NP
O	1206	1209	was	be	VBD	B-VP
O	1210	1218	detected	detect	VBN	I-VP
O	1219	1221	in	in	IN	B-PP
O	1222	1225	all	all	DT	B-NP
O	1226	1228	of	of	IN	B-PP
O	1229	1233	them	them	PRP	B-NP
O	1233	1234	.	.	.	O

O	1235	1238	COX	COX	NN	B-NP
O	1238	1239	-	-	HYPH	I-NP
O	1239	1240	2	2	CD	I-NP
O	1241	1248	protein	protein	NN	I-NP
O	1249	1252	was	be	VBD	B-VP
O	1253	1261	detected	detect	VBN	I-VP
O	1262	1264	in	in	IN	B-PP
O	1265	1270	eight	eight	CD	B-NP
O	1271	1273	of	of	IN	B-PP
O	1274	1277	the	the	DT	B-NP
O	1278	1280	12	12	CD	I-NP
B-Cancer	1281	1291	carcinomas	carcinoma	NNS	I-NP
O	1291	1292	,	,	,	O
O	1293	1300	whereas	whereas	IN	O
O	1301	1310	PPARgamma	PPARgamma	NN	B-NP
O	1311	1318	protein	protein	NN	I-NP
O	1319	1322	was	be	VBD	B-VP
O	1323	1331	detected	detect	VBN	I-VP
O	1332	1334	in	in	IN	B-PP
O	1335	1339	only	only	RB	B-NP
O	1340	1343	two	two	CD	I-NP
O	1344	1349	cases	case	NNS	I-NP
O	1349	1350	.	.	.	O

O	1351	1353	In	In	IN	B-PP
O	1354	1362	addition	addition	NN	B-NP
O	1362	1363	,	,	,	O
O	1364	1373	PPARgamma	PPARgamma	NN	B-NP
O	1374	1381	protein	protein	NN	I-NP
O	1382	1385	was	be	VBD	B-VP
O	1386	1389	not	not	RB	I-VP
O	1390	1398	detected	detect	VBN	I-VP
O	1399	1401	in	in	IN	B-PP
O	1402	1405	all	all	DT	B-NP
O	1406	1408	of	of	IN	B-PP
O	1409	1412	the	the	DT	B-NP
O	1413	1418	eight	eight	CD	I-NP
B-Cancer	1419	1429	carcinomas	carcinoma	NNS	I-NP
O	1430	1432	in	in	IN	B-PP
O	1433	1438	which	which	WDT	B-NP
O	1439	1442	COX	COX	NN	B-NP
O	1442	1443	-	-	HYPH	I-NP
O	1443	1444	2	2	CD	I-NP
O	1445	1452	protein	protein	NN	I-NP
O	1453	1456	was	be	VBD	B-VP
O	1457	1465	detected	detect	VBN	I-VP
O	1465	1466	,	,	,	O
O	1467	1477	suggesting	suggest	VBG	B-VP
O	1478	1482	that	that	IN	B-SBAR
O	1483	1493	expression	expression	NN	B-NP
O	1494	1496	of	of	IN	B-PP
O	1497	1506	PPARgamma	PPARgamma	NN	B-NP
O	1507	1510	and	and	CC	I-NP
O	1511	1514	COX	COX	NN	I-NP
O	1514	1515	-	-	HYPH	O
O	1515	1516	2	2	CD	B-NP
O	1517	1520	was	be	VBD	B-VP
O	1521	1523	in	in	IN	B-PP
O	1524	1525	a	a	DT	B-NP
O	1526	1536	reciprocal	reciprocal	JJ	I-NP
O	1537	1549	relationship	relationship	NN	I-NP
O	1549	1550	.	.	.	O

O	1551	1562	Furthermore	Furthermore	RB	B-ADVP
O	1562	1563	,	,	,	O
O	1564	1566	in	in	IN	B-PP
O	1567	1575	cultured	culture	VBN	B-NP
B-Cell	1576	1583	ovarian	ovarian	JJ	I-NP
I-Cell	1584	1593	carcinoma	carcinoma	NN	I-NP
I-Cell	1594	1599	cells	cell	NNS	I-NP
O	1599	1600	,	,	,	O
O	1601	1608	Western	Western	NN	B-NP
O	1609	1613	blot	blot	NN	I-NP
O	1614	1622	revealed	reveal	VBD	B-VP
O	1623	1627	that	that	IN	B-SBAR
O	1628	1637	PPARgamma	PPARgamma	NN	B-NP
O	1638	1641	and	and	CC	I-NP
O	1642	1645	COX	COX	NN	I-NP
O	1645	1646	-	-	HYPH	O
O	1646	1647	2	2	CD	B-NP
O	1648	1658	expression	expression	NN	I-NP
O	1659	1662	was	be	VBD	B-VP
O	1663	1672	regulated	regulate	VBN	I-VP
O	1673	1683	conversely	conversely	RB	B-ADVP
O	1684	1686	as	as	IN	B-PP
O	1687	1688	a	a	DT	B-NP
O	1689	1695	result	result	NN	I-NP
O	1696	1698	of	of	IN	B-PP
O	1699	1710	stimulation	stimulation	NN	B-NP
O	1711	1713	by	by	IN	B-PP
O	1714	1716	15	15	CD	B-NP
O	1716	1717	-	-	HYPH	I-NP
O	1717	1722	deoxy	deoxy	NN	I-NP
O	1722	1723	-	-	HYPH	O
O	1723	1728	Delta	Delta	NN	B-NP
O	1728	1729	(	(	(	O
O	1729	1731	12	12	CD	B-NP
O	1731	1732	,	,	,	O
O	1733	1735	14	14	CD	B-NP
O	1735	1736	)	)	)	O
O	1737	1740	PGJ	PGJ	NN	B-NP
O	1740	1741	(	(	(	O
O	1741	1742	2	2	CD	B-NP
O	1742	1743	)	)	)	O
O	1744	1745	(	(	(	O
O	1745	1747	15	15	CD	B-NP
O	1747	1748	-	-	HYPH	I-NP
O	1748	1751	PGJ	PGJ	NN	I-NP
O	1751	1752	(	(	(	O
O	1752	1753	2	2	CD	B-NP
O	1753	1754	)	)	)	O
O	1754	1755	)	)	)	O
O	1755	1756	,	,	,	O
O	1757	1758	a	a	DT	B-NP
O	1759	1768	PPARgamma	PPARgamma	NN	I-NP
O	1769	1778	activator	activator	NN	I-NP
O	1778	1779	.	.	.	O

O	1780	1782	In	In	IN	B-PP
O	1783	1791	addition	addition	NN	B-NP
O	1791	1792	,	,	,	O
O	1793	1796	15d	15d	NN	B-NP
O	1796	1797	-	-	HYPH	O
O	1797	1800	PGJ	PGJ	NN	B-NP
O	1800	1801	(	(	(	O
O	1801	1802	2	2	CD	B-NP
O	1802	1803	)	)	)	O
O	1804	1814	suppressed	suppress	VBD	B-VP
O	1815	1821	tumour	tumour	NN	B-NP
O	1822	1830	necrosis	necrosis	NN	I-NP
O	1831	1837	factor	factor	NN	I-NP
O	1837	1838	-	-	HYPH	O
O	1838	1843	alpha	alpha	SYM	O
O	1843	1844	-	-	HYPH	O
O	1844	1851	induced	induce	VBN	B-VP
O	1851	1852	-	-	HYPH	B-NP
O	1852	1855	COX	COX	NN	I-NP
O	1855	1856	-	-	HYPH	O
O	1856	1857	2	2	CD	B-NP
O	1858	1868	expression	expression	NN	I-NP
O	1868	1869	,	,	,	O
O	1870	1880	confirming	confirm	VBG	B-VP
O	1881	1884	the	the	DT	B-NP
O	1885	1895	reciprocal	reciprocal	JJ	I-NP
O	1896	1907	correlation	correlation	NN	I-NP
O	1908	1915	between	between	IN	B-PP
O	1916	1919	COX	COX	NN	B-NP
O	1919	1920	-	-	HYPH	O
O	1920	1921	2	2	CD	B-NP
O	1922	1925	and	and	CC	O
O	1926	1935	PPARgamma	PPARgamma	NN	B-NP
O	1935	1936	.	.	.	O

O	1937	1941	From	From	IN	B-PP
O	1942	1947	these	these	DT	B-NP
O	1948	1955	results	result	NNS	I-NP
O	1955	1956	,	,	,	O
O	1957	1959	it	it	PRP	B-NP
O	1960	1963	was	be	VBD	B-VP
O	1964	1973	suggested	suggest	VBN	I-VP
O	1974	1978	that	that	IN	B-SBAR
O	1979	1988	PPARgamma	PPARgamma	NN	B-NP
O	1989	1999	activation	activation	NN	I-NP
O	2000	2005	might	might	MD	B-VP
O	2006	2014	suppress	suppress	VB	I-VP
O	2015	2018	COX	COX	NN	B-NP
O	2018	2019	-	-	HYPH	O
O	2019	2020	2	2	CD	B-NP
O	2021	2031	expression	expression	NN	I-NP
O	2032	2035	via	via	IN	B-PP
O	2036	2039	the	the	DT	B-NP
O	2040	2047	nuclear	nuclear	JJ	I-NP
O	2048	2054	factor	factor	NN	I-NP
O	2054	2055	-	-	HYPH	B-NP
O	2055	2061	kappaB	kappaB	NN	I-NP
O	2062	2069	pathway	pathway	NN	I-NP
O	2070	2072	in	in	IN	B-PP
O	2073	2076	the	the	DT	B-NP
B-Cell	2077	2084	ovarian	ovarian	JJ	I-NP
I-Cell	2085	2094	carcinoma	carcinoma	NN	I-NP
I-Cell	2095	2100	cells	cell	NNS	I-NP
O	2101	2104	and	and	CC	O
O	2105	2109	that	that	IN	B-SBAR
O	2110	2113	low	low	JJ	B-NP
O	2114	2124	expression	expression	NN	I-NP
O	2125	2127	of	of	IN	B-PP
O	2128	2137	PPARgamma	PPARgamma	NN	B-NP
O	2138	2141	and	and	CC	O
O	2142	2146	high	high	JJ	B-NP
O	2147	2157	expression	expression	NN	I-NP
O	2158	2160	of	of	IN	B-PP
O	2161	2164	COX	COX	NN	B-NP
O	2164	2165	-	-	HYPH	O
O	2165	2166	2	2	CD	B-NP
O	2167	2172	might	might	MD	B-VP
O	2173	2175	be	be	VB	I-VP
O	2176	2184	involved	involve	VBN	I-VP
O	2185	2187	in	in	IN	B-PP
O	2188	2202	carcinogenesis	carcinogenesis	NN	B-NP
O	2203	2206	and	and	CC	I-NP
O	2207	2218	progression	progression	NN	I-NP
O	2219	2221	of	of	IN	B-PP
B-Cancer	2222	2229	ovarian	ovarian	JJ	B-NP
I-Cancer	2230	2237	tumours	tumour	NNS	I-NP
O	2237	2238	.	.	.	O

